- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02247583
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment (IPSOC)
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.
Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.
The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.
The following aspects will be investigated:
- Intrinsic desire for information about treatment.
- Patient satisfaction with treatment information.
- Patient satisfaction with treatment.
- Medication adherence.
- Health-related quality of life.
- The role of different health care professionals in the treatment of RCC with oral drugs
This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Leuven, Belgien, 3000
- Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study
Exclusion Criteria:
- Patients who are not able to understand Dutch or French will be excluded from the study
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
mRCC patients
Patients with metastatic renal cell carcinoma
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Medication adherence
Tidsram: one year
|
At the first visit patients will receive their anti-cancer medication by the hospital in a pill box which electronically records openings cf.
Medication Event Monitoring System (MEMS®, Aardex).
The recorded information in this chip will be read in the hospital pharmacy each time the patient gets new capsules.
This information is strictly confidential and can only be consulted by the research team at the KULeuven.
|
one year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Extent of Information Desire (EID)
Tidsram: one year
|
Extent of information desire will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Patient Satisfaction with Cancer Treatment Education (Ps-CaTE)
Tidsram: one year
|
Satisfaction with cancer treatment information will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Morisky Medication Adherence Scale (MMAS)
Tidsram: one year
|
Medication adherence will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Cancer Therapy Satisfaction Questionnaire (CTSQ)
Tidsram: one year
|
Satisfaction with cancer treatment will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Functional Assessment of Cancer Therapy - General (FACT-G)
Tidsram: one year
|
Health-related quality of life will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Functional Kidney Symptom Index (FKSI)
Tidsram: one year
|
Health-related quality of life will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
|
Satisfaction With Pharmacist (SwiP)
Tidsram: one year
|
Satisfaction with the pharmacist will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
|
one year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Veerle Foulon, Professor, Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- VF/2010/03
- s52586 (Registeridentifierare: Clinical Trial Center UZ Leuven)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .